CPC 111

Drug Profile

CPC 111

Alternative Names: Cordox

Latest Information Update: 13 Oct 2005

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Questcor Pharmaceuticals
  • Class Antianaemics
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Heart failure; Heart transplant rejection; Perioperative ischaemia; Reperfusion injury; Sickle cell anaemia; Transplant rejection

Most Recent Events

  • 13 Oct 2005 Discontinued - Phase-I for Heart failure in China (IV)
  • 13 Oct 2005 Discontinued - Phase-I for Heart transplant rejection in Europe (unspecified route)
  • 13 Oct 2005 Discontinued - Phase-II for Heart failure in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top